Five generic drugs banned for side effects

The Directorate General of Drug Administration has banned manufacturing and importing of raw materials of five generic drugs of local pharmaceutical companies, terming the drugs  threats to public health.

The five drugs – Pioglitazon, Rosiglitazone, Gatifloxacin, Tegaserod and Sibutramine – were banned as they had excessive adverse reaction; while decision on Flupenthixol-Melitracen – another drug which was previously recommended for a ban – would later be made following another review by the ADRAC.

The decision was made on April 21 by the National Adverse Drug Reaction Advisory Committee, led by Health Secretary MM Niazuddin.

A previous meeting by the DGDA’s Adverse Drug Reaction Advisory Committee (ADRAC) had recommended a ban on six generic drugs.

Selim Barami, director of the DGDA, confirmed the bans and said no company would be allowed to further manufacture or import raw materials of the drugs.

When asked why Flupenthixol-Melitracen was not banned, Barami told the Dhaka Tribune that leaders of the Bangladesh Association of Pharmaceuticals Industries (BAPI) recently met with DGDA officials and submitted a letter saying there was no definite proof of any adverse effect of Flupenthixol-Melitracen. BAPI leaders also claimed that the drug has been used by several developed country including Switzerland.

Following their request, authorities decided to send the issue of the drug for review at the ADRAC again, Barami added.

The DGDA could not provide the exact number of companies currently manufacturing the banned drugs. However, an official, seeking anonymity, said the number would be around 20-25, adding that most of the banned drugs were still in the market.

Out of the banned generic drugs, Pioglitazone and Rosiglitazone are used for the treatment of diabetes, while Gatifloxacin (except eye drops), Tegaserod and Sibutramine are used for treating patients with bacterial infections, irritable bowel syndrome and obesity respectively.